Monograph

J05AH02 - Oseltamivir

Not porphyrinogenic

Rationale

No CYP-interactions.

Chemical description

Antiviral neuramidinase inhibitor used perorally (up to 75 mg x 2 daily for 5 days) in symptomatic influenza in adults and children > 1 year, and as prevention after viral exposure in individuals > 13 years. About 90% of the absorbed dose is metabolzed by liver esterases, the carboxylated metabolite excreted in urine. CYPs are not involved in the biotransformation.

IPNet drug reports

Uneventful use reported in 2 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes J05A / J05AH or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames